JP2021534217A - 視力を改善するためのａ−２−アドレナリン受容体アゴニストの使用 - Google Patents

視力を改善するためのａ−２−アドレナリン受容体アゴニストの使用 Download PDF

Info

Publication number
JP2021534217A
JP2021534217A JP2021510070A JP2021510070A JP2021534217A JP 2021534217 A JP2021534217 A JP 2021534217A JP 2021510070 A JP2021510070 A JP 2021510070A JP 2021510070 A JP2021510070 A JP 2021510070A JP 2021534217 A JP2021534217 A JP 2021534217A
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
use according
improvement
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021510070A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020041340A5 (https=
JP2021534217A5 (https=
Inventor
モハメド ディバス
ダニエル ダブリュ ギル
ウェイン チェン
ミゲル アルカンタラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of JP2021534217A publication Critical patent/JP2021534217A/ja
Publication of JPWO2020041340A5 publication Critical patent/JPWO2020041340A5/ja
Publication of JP2021534217A5 publication Critical patent/JP2021534217A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021510070A 2018-08-21 2019-08-20 視力を改善するためのａ−２−アドレナリン受容体アゴニストの使用 Pending JP2021534217A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862720671P 2018-08-21 2018-08-21
US62/720,671 2018-08-21
PCT/US2019/047305 WO2020041340A1 (en) 2018-08-21 2019-08-20 The use of alpha-2-adrenergic receptor agonists for improving vision

Publications (3)

Publication Number Publication Date
JP2021534217A true JP2021534217A (ja) 2021-12-09
JPWO2020041340A5 JPWO2020041340A5 (https=) 2022-08-26
JP2021534217A5 JP2021534217A5 (https=) 2022-08-26

Family

ID=67841225

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021510070A Pending JP2021534217A (ja) 2018-08-21 2019-08-20 視力を改善するためのａ−２−アドレナリン受容体アゴニストの使用

Country Status (17)

Country Link
US (4) US20210205273A1 (https=)
EP (1) EP3840750A1 (https=)
JP (1) JP2021534217A (https=)
KR (1) KR20210047323A (https=)
CN (1) CN112823003A (https=)
AR (1) AR115991A1 (https=)
AU (1) AU2019325486A1 (https=)
BR (1) BR112021003295A2 (https=)
CA (1) CA3110318A1 (https=)
CL (1) CL2021000440A1 (https=)
CO (1) CO2021003460A2 (https=)
IL (1) IL280990A (https=)
MX (1) MX2021002112A (https=)
PH (1) PH12021550372A1 (https=)
SG (1) SG11202101730SA (https=)
TW (1) TW202021584A (https=)
WO (1) WO2020041340A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023514732A (ja) * 2020-02-20 2023-04-07 アラーガン、インコーポレイテッド アルファ－２－アドレナリン受容体アゴニストの医薬組成物および視力を改善するためのその使用
US12023276B2 (en) 2021-02-24 2024-07-02 Ocular Therapeutix, Inc. Intracanalicular depot inserter device
AU2024217271A1 (en) * 2023-02-08 2025-09-18 Bausch + Lomb Ireland Limited Alpha-2-adrenergic agonists for improving vision

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09507216A (ja) * 1993-12-17 1997-07-22 ザ、プロクター、エンド、ギャンブル、カンパニー ５−（２−イミダゾリニルアミノ）ベンゾイミダゾール誘導体、それらの製法及びα−２−アドレノセプター作動剤としてのそれらの用途
JP2007535552A (ja) * 2004-04-30 2007-12-06 アラーガン、インコーポレイテッド α−２アドレナリン受容体アゴニストの眼内インプラントおよび視力の向上方法
JP2008540552A (ja) * 2005-05-10 2008-11-20 アラーガン、インコーポレイテッド 増大した前部クリアランス速度を有するα−２アドレナリン受容体アゴニストを用いる眼科治療
JP2016529297A (ja) * 2013-08-28 2016-09-23 プレスバイオピア・セラピーズ・エル・エル・シー 老視を治療するための組成物及び方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5459133A (en) * 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
US6495583B1 (en) 1997-03-25 2002-12-17 Synaptic Pharmaceutical Corporation Benzimidazole derivatives
US8529927B2 (en) * 2004-04-30 2013-09-10 Allergan, Inc. Alpha-2 agonist polymeric drug delivery systems
EP3085358B1 (en) 2010-01-22 2017-11-01 Allergan, Inc. Intracameral sustained release therapeutic agent implants
WO2012149381A1 (en) * 2011-04-28 2012-11-01 Alpha Synergy Development, Inc. Compositions and methods for improving night vision
US10507245B2 (en) * 2012-07-19 2019-12-17 Luis Felipe Vejarano Restrepo Ophthalmic formulation and method for ameliorating presbyopia
WO2014143754A2 (en) 2013-03-15 2014-09-18 Allergan, Inc. Prostamide-containing intraocular implant
JP2016515583A (ja) 2013-03-27 2016-05-30 フォーサイト ヴィジョンファイブ、インク．ＦｏｒＳｉｇｈｔ ＶＩＳＩＯＮ５， Ｉｎｃ． オキュラー・インサートおよびその使用方法
ES2834964T3 (es) 2013-04-01 2021-06-21 Allergan Inc Sistema de administración de fármacos mediante microesferas para liberación intraocular sostenida
CN103338483B (zh) * 2013-07-24 2016-08-10 成都西加云杉科技有限公司 数据分流方法、数据分流设备及异构网络
US20160296532A1 (en) 2015-04-13 2016-10-13 Forsight Vision5, Inc. Ocular Insert Composition of a Semi-Crystalline or Crystalline Pharmaceutically Active Agent
US11077053B2 (en) * 2018-08-21 2021-08-03 Allergan, Inc. Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09507216A (ja) * 1993-12-17 1997-07-22 ザ、プロクター、エンド、ギャンブル、カンパニー ５−（２−イミダゾリニルアミノ）ベンゾイミダゾール誘導体、それらの製法及びα−２−アドレノセプター作動剤としてのそれらの用途
JP2007535552A (ja) * 2004-04-30 2007-12-06 アラーガン、インコーポレイテッド α−２アドレナリン受容体アゴニストの眼内インプラントおよび視力の向上方法
JP2008540552A (ja) * 2005-05-10 2008-11-20 アラーガン、インコーポレイテッド 増大した前部クリアランス速度を有するα−２アドレナリン受容体アゴニストを用いる眼科治療
JP2016529297A (ja) * 2013-08-28 2016-09-23 プレスバイオピア・セラピーズ・エル・エル・シー 老視を治療するための組成物及び方法

Also Published As

Publication number Publication date
WO2020041340A1 (en) 2020-02-27
BR112021003295A2 (pt) 2021-05-18
AU2019325486A1 (en) 2021-03-25
KR20210047323A (ko) 2021-04-29
CO2021003460A2 (es) 2021-04-08
AR115991A1 (es) 2021-03-17
EP3840750A1 (en) 2021-06-30
MX2021002112A (es) 2021-07-16
US20220288031A1 (en) 2022-09-15
SG11202101730SA (en) 2021-03-30
PH12021550372A1 (en) 2021-11-29
IL280990A (en) 2021-04-29
US20240358682A1 (en) 2024-10-31
US20210205273A1 (en) 2021-07-08
CN112823003A (zh) 2021-05-18
CA3110318A1 (en) 2020-02-27
CL2021000440A1 (es) 2021-09-20
TW202021584A (zh) 2020-06-16
US20220160623A1 (en) 2022-05-26

Similar Documents

Publication Publication Date Title
US20240358682A1 (en) Use of alpha-2-adrenergic receptor agonists for improving vision
RU2657514C2 (ru) Офтальмологический состав и способ для облегчения пресбиопии
JP2025168426A (ja) 眼科用医薬組成物及びそれに関する使用
WO2009077736A2 (en) Optical correction
US20240390330A1 (en) Alpha-2-adrenergic receptor agonists for reducing redness and increasing whiteness in eyes and other ophthalmic purposes
Montés-Micó et al. Optical quality of the eye after lens replacement with a pseudoaccommodating intraocular lens
US11077053B2 (en) Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia
US20240335425A1 (en) Pharmaceutical compositions of alpha-2-adrenergic receptor agonists and their use for improving vision
AU2017201568B2 (en) Optical correction
HK40053072A (en) The use of alpha-2-adrenergic receptor agonists for improving vision

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220818

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220818

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230726

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230727

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231027

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231227

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240318